The current and future landscape of urinary thromboxane testing to evaluate atherothrombotic risk.
作者： Alan S. Maisel , Sean-Xavier Neath , Peter A. McCullough , Robert L. Jesse , Alan H.B. Wu
DOI: 10.3909/RICM0739
关键词:
摘要: Biomarker testing for efficacy of therapy is an accepted way clinicians to individualize dosing genetic and/or environmental factors that may be influencing a treatment regimen. Aspirin used by nearly 43 million Americans on regular basis reduce risks associated with various atherothrombotic diseases. Despite its widespread use, many are unaware the link between suboptimal response aspirin and increased risk inferior clinical outcomes in several disease states, biomarker not performed as routinely other therapeutic areas. This article reviews laboratory aspects determining whole-body thromboxane production, particularly it pertains assessment responsiveness.
researchgate.net 
sci-hub.st 参考文章(23)
M. T. OLSON, T. S. KICKLER, J. A. LAWSON, R. C. MCLEAN, J. JANI, G. A. FITZGERALD, J. J. RADE, Effect of assay specificity on the association of urine 11-dehydro thromboxane B2 determination with cardiovascular risk. Journal of Thrombosis and Haemostasis. ,vol. 10, pp. 2462- 2469 ,(2012) , 10.1111/JTH.12026
Artur-Aron Weber, Katja C Zimmermann, Jutta Meyer-Kirchrath, Karsten Schrör, Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance. The Lancet. ,vol. 353, pp. 900- 901 ,(1999) , 10.1016/S0140-6736(99)00498-5
Michael J. Thun, Eric J. Jacobs, Carlo Patrono, The role of aspirin in cancer prevention Nature Reviews Clinical Oncology. ,vol. 9, pp. 259- 267 ,(2012) , 10.1038/NRCLINONC.2011.199
M. L. Foegh, Y. Zhao, L. Madren, M. Rolnick, T. O. Stair, K. S. Huang, P. W. Ramwell, Urinary thromboxane A2 metabolites in patients presenting in the emergency room with acute chest pain Journal of Internal Medicine. ,vol. 235, pp. 153- 161 ,(1994) , 10.1111/J.1365-2796.1994.TB01049.X
Gary P. O'Neill, Anthony W. Ford-Hutchinson, Expression of mRNA for cyclooxygenase‐1 and cyclooxygenase‐2 in human tissues FEBS Letters. ,vol. 330, pp. 157- 160 ,(1993) , 10.1016/0014-5793(93)80263-T
G A FitzGerald, A K Pedersen, C Patrono, Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. Circulation. ,vol. 67, pp. 1174- 1177 ,(1983) , 10.1161/01.CIR.67.6.1174
Silvia Pascale, Giovanna Petrucci, Alfredo Dragani, Aida Habib, Francesco Zaccardi, Francesca Pagliaccia, Davide Pocaterra, Enzo Ragazzoni, Giancarlo Rolandi, Bianca Rocca, Carlo Patrono, Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target Blood. ,vol. 119, pp. 3595- 3603 ,(2012) , 10.1182/BLOOD-2011-06-359224
L.J. Roberts, B.J. Sweetman, N.A. Payne, J.A. Oates, Metabolism of thromboxane B2 in man. Identification of the major urinary metabolite. Journal of Biological Chemistry. ,vol. 252, pp. 7415- 7417 ,(1977) , 10.1016/S0021-9258(17)40976-8
B. F. McAdam, F. Catella-Lawson, I. A. Mardini, S. Kapoor, J. A. Lawson, G. A. FitzGerald, Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proceedings of the National Academy of Sciences of the United States of America. ,vol. 96, pp. 272- 277 ,(1999) , 10.1073/PNAS.96.1.272
Andrew P DeFilippis, Oluwasegun S Oloyede, Efstathia Andrikopoulou, Amy K Saenger, Joel M Palachuvattil, Yetunde A Fasoro, Eliseo Guallar, Roger S Blumenthal, Thomas S Kickler, Allan S Jaffe, Gary Gerstenblith, Steven P Schulman, Jeffrey J Rade, None, Thromboxane A2 Generation, in the Absence of Platelet COX-1 Activity, in Patients With and Without Atherothrombotic Myocardial Infarction Circulation. ,vol. 77, pp. 2786- 2792 ,(2013) , 10.1253/CIRCJ.CJ-12-1421